Skip Ribbon Commands
Skip to main content
Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

January 26, 2021

Services that require precertification for Medicare Advantage members

As of January 1, 2021, this list applies to all Independence Blue Cross HMO, POS, and PPO products.

This applies to services performed on an elective, nonemergency basis

Because a service or item is subject to precertification, it does not guarantee coverage. The terms and conditions of your benefit plan must be reviewed to determine if any of these services or items are excluded.

You can find additional information regarding preapproval/precertification, member cost-sharing and prescription drug coverage on the Independence Preapproval/Precertification Requirements, Member Cost-Sharing, and Prescription Drug Formulary Lists page.

All home-care services (including infusion therapy in the home)
 
Inpatient services

  • Acute rehabilitation admissions 
  • Elective surgical and nonsurgical inpatient admissions 
  • Inpatient hospice admissions
  • Long term acute care (LTAC) facility admissions 
  • Skilled nursing facility admissions

Cardiology procedures

​Precertification is performed by AIM Specialty Health®, an independent company. To access the complete list of AIM Clinical Appropriateness Guidelines for Cardiology and Arterial Ultrasound, click here. 

  • Arterial ultrasound 
  • Diagnostic coronary angiography
  • Percutaneous coronary intervention

Any procedure, device, or service that may potentially be considered experimental or investigational including:

  • New emerging technology/procedures, as well as existing technology and procedures applied for new uses and treatments

​Procedures

  • Bronchial thermoplasty
    31660, 31661
     
  • Cochlear implant surgery and associated supplies/bone-anchored (osseointegrated) hearing aids, implantable bone conduction hearing aids
    69714, 69715, 69717, 69718, 69930, L8619, L8627, L8628, L8629, L8690, L8691, L8692, L8693
     
  • Obesity surgery
    43644, 43645, 43659, 43770, 43771, 43772, 43773, 43774, 43775, 43842, 43843, 43845, 43846, 43847, 43848, 43886, 43887, 43888, 43999
     
  • Uvulopalatopharyngoplasty (UPPP)
    42145

Musculoskeletal Procedures​

Precertification is performed by AIM Specialty Health®, an independent company. For additional information, refer to the current version of Medical Policy #00.01.66: Musculoskeletal Services.
  • Bone graft substitutes and bone morphogenetic proteins for spine surgery 
  • Cervical decompression with or without fusion cervical disc arthroplasty
  • Hip arthroplasty 
  • Hip arthroscopy and open procedures 
  • Knee arthroplasty 
  • Knee arthroscopy and open procedures 
  • Lumbar disc arthroplasty 
  • Lumbar discectomy, foraminotomy, and laminotomy 
  • Lumbar fusion and treatment of spinal deformity (including scoliosis and kyphosis) 
  • Lumbar laminectomy 
  • Meniscal allograft transplantation of the knee 
  • Shoulder arthroplasty
  • Shoulder arthroscopy and open procedures
  • Treatment of osteochondral defects 
  • Vertebroplasty/Kyphoplasty

Interventional pain management services


Precertification is performed by AIM Specialty Health®, an independent company. For additional information, refer to the current version of Medical Policy #00.01.66: Musculoskeletal Services.
  • Epidural Injection Procedures and Diagnostic Selective Nerve Root Blocks
  • Paravertebral Facet Injection/Nerve Block/Neurolysis
  • Regional Sympathetic Nerve Block 
  • Sacroiliac joint injections 
  • Implanted spinal cord stimulators

Reconstructive procedures and potentially cosmetic procedures

  • Blepharoplasty/ptosis repair
    15820, 15821, 15822, 15823, 67900, 67901, 67902, 67903, 67904, 67906, 67908, 67909 

     
  • Bone graft, genioplasty and mentoplasty
    21120, 21121, 21122, 21123

     
  • Breast Reconstruction
    11920, 11921, 11922, 11970, 11971, 15271, 15272, 15769, 15771, 15772, 15773, 15774, 15777, 19350, 19355, 19357, 19361, 19364, 19367, 19368, 19369, 19380, Q4100, Q4107, Q4130, S2066, S2067, S2068

     
  • Breast Reduction
    15877, 19318

     
  • Breast Augmentation/Mammoplasty
    19325

      
  • Breast Mastopexy
    19316

     
  • Insertion of Breast Implants
    19340, 19342, 19396

     
  • Removal of Breast Implants
    19328, 19330, 19370, 19371

     
  • Canthopexy/Canthoplasty
    21280, 21282, 67950

     
  • Cervicoplasty
    15819
     
  • Chemical peels
    15788, 15789, 15792, 15793
     
  • Dermabrasion
    15780, 15781, 15782, 15783
     
  • Excision of excessive skin and/or subcutaneous tissue
    15830, 15832, 15833, 15834, 15835, 15836, 15837, 15838, 15839
     
  • Gender reassignment surgery
    11960, 19303, 53430, 54125, 54400, 54401, 54405, 54520, 54660, 54690, 55175, 55180, 57106, 57110, 58150, 58180, 58260, 58262, 58275, 58290, 58291, 58541, 58542, 58543, 58544, 58550, 58552, 58553, 58554, 58570, 58571, 58572, 58573, 58720

  • Genetically and bio-engineered skin substitutes for wound care
    C1849, Q4100, Q4101, Q4102, Q4103, Q4104, Q4105, Q4106, Q4107, Q4108, Q4110, Q4111, Q4113, Q4114, Q4115, Q4117, Q4118, Q4121, Q4122, Q4123, Q4124, Q4126, Q4127, Q4132, Q4133, Q4134, Q4135, Q4136, Q4137, Q4139, Q4140, Q4141, Q4145, Q4146, Q4147, Q4148, Q4149, Q4151, Q4152, Q4153, Q4154, Q4155, Q4156, Q4157, Q4158, Q4159, Q4160, Q4161, Q4162, Q4163, Q4164, Q4165, Q4166, Q4167, Q4168, Q4169, Q4170, Q4171, Q4173, Q4174, Q4175, Q4176, Q4177, Q4178, Q4179, Q4180, Q4181, Q4182, Q4205, Q4206, Q4208, Q4209, Q4210, Q4211, Q4214, Q4215, Q4216, Q4217, Q4218, Q4219, Q4220, Q4221, Q4222, Q4227, Q4228, Q4229, Q4230, Q4231, Q4232, Q4233, Q4234, Q4235, Q4236, Q4237, Q4238, Q4239, Q4244, Q4245, Q4246, Q4247, Q4248, Q4249, Q4250, Q4254, Q4255

  • Hair transplant
    15775, 15776
     
  • Injectable dermal fillers
    11950, 11951, 11952, 11954, Q2026, Q2028
     
  • Keloid removal
    13100, 13101, 13102, 13120, 13121, 13122, 13131, 13132, 13133, 13151, 13152, 13153, 14000, 14001, 14020, 14021, 14040, 14041, 14060, 14061, 14301, 14302, 15002, 15003, 15004, 15005, 15040, 15050, 15100, 15101, 15110, 15111, 15115, 15116, 15120, 15121, 15130, 15131, 15135, 15136, 15150, 15151, 15152, 15155, 15156, 15157, 15200, 15201, 15220, 15221, 15240, 15241, 15260, 15261, 15271, 15272, 15273, 15274, 15275, 15276, 15277, 15278, 15570, 15572, 15574, 15576, 15600, 15610, 15620, 15630, 15650, 15731, 15733, 15734, 15736, 15738, 15740, 15750, 15756, 15757, 15758, 15760, 15770, 15780, 15781, 15782, 15783, 15786, 15787, 31830

  • Lipectomy, liposuction, or any other excess fat-removal procedure
    15832, 15833, 15834, 15835, 15836, 15837, 15838, 15839, 15876, 15877, 15878, 15879

  • Otoplasty
    13151, 13152, 13153, 14060, 14061, 15260, 15261, 21235, 69300, 69399

  • Rhinoplasty
    30400, 30410, 30420, 30430, 30435, 30450
     
  • Rhytidectomy
    15824, 15825, 15826, 15828, 15829, 15838, 15839, 15876
     
  • Scar revision
    13100, 13101, 13102, 13120, 13121, 13122, 13131, 13132, 13133, 13151, 13152, 13153, 14000, 14001, 14020, 14021, 14040, 14041, 14060, 14061, 14301, 14302, 15002, 15003, 15004, 15005, 15040, 15050, 15100, 15101, 15110, 15111, 15115, 15116, 15120, 15121, 15130, 15131, 15135, 15136, 15150, 15151, 15152, 15155, 15156, 15157, 15200, 15201, 15220, 15221, 15240, 15241, 15260, 15261, 15271, 15272, 15273, 15274, 15275, 15276, 15277, 15278, 15570, 15572, 15574, 15576, 15600, 15610, 15620, 15630, 15650, 15731, 15733, 15734, 15736, 15738, 15740, 15750, 15756, 15757, 15758, 15760, 15770, 15780, 15781, 15782, 15783, 15786, 15787, 31830
     
  • Skin closures
    13100, 13101, 13102, 13120, 13121, 13122, 13131, 13132, 13133, 13151, 13152, 13153, 14000, 14001, 14020, 14021, 14040, 14041, 14060, 14061, 14301, 14302, 15002, 15003, 15004, 15005, 15040, 15050, 15100, 15101, 15110, 15111, 15115, 15116, 15120, 15121, 15130, 15131, 15135, 15136, 15150, 15151, 15152, 15155, 15156, 15157, 15200, 15201, 15220, 15221, 15240, 15241, 15260, 15261, 15271, 15272, 15273, 15274, 15275, 15276, 15277, 15278, 15570, 15572, 15574, 15576, 15600, 15610, 15620, 15630, 15650, 15731, 15733, 15734, 15736, 15738, 15740, 15750, 15756, 15757, 15758, 15760, 15770

  • Surgery for varicose veins, including perforators and sclerotherapy
    36465, 36466, 36470, 36471, 36475, 36476, 36478, 36479, 37500, 37700, 37718, 37722, 37735, 37760, 37761, 37765, 37766, 37780, 37785, 37799 

​Elective (nonemergency) ground, air, and sea ambulance transportation

A0140, A0426, A0428, A0430, A0431, A0434, S9960, S9961

Outpatient private-duty nursing

S9123, S9124

Day rehabilitation programs

0931, 0932

Outpatient radiation therapy

Precertification review is provided by CareCore National, LLC d/b/a eviCore healthcare (eviCore), an independent company. To access the eviCore website, click here.

Radiology

Precertification is performed by AIM Specialty Health®, an independent company. To access the complete list of AIM Specialty Health Diagnostic Imaging Utilization Management Clinical Guidelines, click here.

  • CT  
  • CTA 
  • Echocardiography services
    • Testing transthoracic echocardiography (TTE)
    • Stress echocardiography (SE)
    • Transesophageal echocardiography (TE)
  • MRA 
  • MRI 
  • Nuclear cardiology 
  • PET scans

Prosthetics/orthoses including:

  • Custom ankle-foot orthoses
    L1900, L1904, L1907, L1920, L1940, L1945, L1950, L1960, L1970, L1980, L1990, L2106, L2108, L4631
     
  • Custom knee-ankle-foot orthoses
    L2000, L2005, L2010, L2020, L2030, L2034, L2036, L2037, L2038, L2126, L2128
     
  • Custom knee braces
    L1834, L1840, L1844, L1846, L1860
  • Custom limb prosthetics including accessories/components
    L5010, L5020, L5050, L5060, L5100, L5105, L5150, L5160, L5200, L5210, L5220, L5230, L5250, L5270, L5280, L5301, L5312, L5321, L5331, L5341, L5510, L5520, L5530, L5535, L5540, L5560, L5570, L5580, L5585, L5590, L5595, L5600, L5610, L5611, L5613, L5614, L5616, L5617, L5618, L5620, L5622, L5624, L5626, L5628, L5629, L5630, L5631, L5632, L5634, L5636, L5637, L5638, L5639, L5640, L5642, L5643, L5644, L5645, L5646, L5647, L5648, L5649, L5650, L5651, L5652, L5653, L5654, L5655, L5656, L5658, L5661, L5665, L5666, L5668, L5670, L5671, L5672, L5673, L5676, L5677, L5678, L5679, L5680, L5681, L5682, L5683, L5684, L5685, L5686, L5688, L5690, L5692, L5694, L5695, L5696, L5697, L5698, L5699, L5700, L5701, L5702, L5703, L5704, L5705, L5706, L5707, L5710, L5711, L5712, L5714, L5716, L5718, L5722, L5724, L5726, L5728, L5780, L5781, L5782, L5785, L5790, L5795, L5810, L5811, L5812, L5814, L5816, L5818, L5822, L5824, L5826, L5828, L5830, L5840, L5845, L5848, L5850, L5855, L5856, L5857, L5858, L5859, L5910, L5920, L5925, L5930, L5940, L5950, L5960, L5962, L5964, L5966, L5968, L5970, L5971, L5972, L5973, L5974, L5975, L5976, L5978, L5979, L5980, L5981, L5982, L5984, L5985, L5986, L5987, L5988, L5990, L5999, L6000, L6010, L6020, L6050, L6055, L6100, L6110, L6120, L6130, L6320, L6350, L6360, L6370, L6400, L6450, L6500, L6550, L6570, L6580, L6582, L6584, L6586, L6588, L6590, L6600, L6605, L6610, L6611, L6615, L6616, L6620, L6621, L6623, L6624, L6625, L6628, L6629, L6630, L6632, L6635, L6637, L6638, L6640, L6641, L6642, L6645, L6646, L6647, L6648, L6650, L6655, L6660, L6665, L6670, L6672, L6675, L6676, L6677, L6680, L6682, L6684, L6686, L6687, L6688, L6689, L6690, L6691, L6692, L6693, L6694, L6695, L6696, L6697, L6698, L6703, L6704, L6706, L6707, L6708, L6709, L6711, L6712, L6713, L6714, L6715, L6721, L6722, L6805, L6810, L6880, L6881, L6882, L6883, L6884, L6885, L6890, L6895, L6900, L6905, L6910, L6915, L6920, L6925, L6930, L6935, L6940, L6945, L6950, L6955, L6960, L6965, L6970, L6975, L7007, L7008, L7009, L7040, L7045, L7170, L7180, L7181, L7185, L7186, L7190, L7191, L7260, L7400, L7401, L7402, L7403, L7404, L7405, L7499 

Selected durable medical equipment (DME)

  • Bone growth stimulators
    E0747, E0760
     
  • Bone growth stimulator, electrical, noninvasive, spinal
    Precertification is performed by AIM Specialty Health®, an independent company. For additional information, refer to the current version of Medical Policy #00.01.66: Musculoskeletal Services.
     
  • Bone-anchored (osseointegrated) hearing aids
    L8690, L8691, L8692, L8693, L8694
     
  • Continuous positive airway pressure (CPAP) devices, bi-level (Bi-PAP) devices, and all supplies
    Precertification is performed by AIM Specialty Health®, an independent company. To access the complete list of AIM Specialty Health Sleep Disorder Management Diagnostic & Treatment Guidelines, click here.
     
  • Dynamic adjustable and static progressive stretching devices (excludes CPMs)
    E1800, E1802, E1805, E1810, E1812, E1825, E1830
     
  • Electric, power, and motorized wheelchairs including custom accessories
    E1002, E1003, E1004, E1005, E1006, E1007, E1008, E1009, E1010, E1012, E1239, E2291, E2292, E2293, E2294 E2310, E2311, E2312, E2313, E2321, E2322, E2323, E2324, E2325, E2326, E2327, E2328, E2329, E2330, E2331 E2340, E2341, E2342, E2343, E2351, E2373, E2377, E2603, E2604, E2605, E2606, E2607, E2608, E2609, E2613 E2614, E2615, E2616, E2617, E2620, E2621, E2622, E2623, E2624, E2625, E2626, E2627, E2628, E2629, E2630 K0010, K0011, K0012, K0013, K0014, K0056, K0108, K0813, K0814, K0815, K0816, K0820, K0821, K0822, K0823 K0824, K0825, K0826, K0827, K0828, K0829, K0835, K0836, K0837, K0838, K0839, K0840, K0841, K0842, K0843 K0848, K0849, K0850, K0851, K0852, K0853, K0854, K0855, K0856, K0857, K0858, K0859, K0860, K0861, K0862 K0863, K0864, K0890, K0891, K0898
     
  • Insulin pumps
    E0784, E0787, S1034
     
  • Manual wheelchairs with the exception of those that are rented
    E0958, E1002, E1003, E1004, E1005, E1006, E1007, E1008, E1009, E1010, E1012, E1031, E1037, E1038, E1039 E1050, E1060, E1070, E1083, E1084, E1085, E1086, E1087, E1088, E1089, E1090, E1092, E1093, E1100, E1110  E1130, E1140, E1150, E1160, E1161, E1170, E1171, E1172, E1180, E1190, E1195, E1200, E1220, E1221, E1222  E1223, E1224, E1229, E1231, E1232, E1233, E1234, E1235, E1236, E1237, E1238, E1240, E1250, E1260, E1270  E1280, E1285, E1290, E1295, E2291, E2292, E2293, E2294, E2295, E2603, E2604, E2605, E2606, E2607, E2608  E2609, E2613, E2614, E2615, E2616, E2617, E2620, E2621, E2622, E2623, E2624, E2625, E2626, E2627, E2628  E2629, E2630, K0001, K0002, K0003, K0004, K0005, K0006, K0007, K0008, K0009, K0108
     
  • Negative pressure wound therapy
    A6550, A9272, E2402, K0743, K0744, K0745, K0746

  • Neuromuscular stimulators
    E0744, E0745, E0764, E0770
     
  • Power operated vehicles (POV)
    E1230, K0800, K0801, K0802, K0812
     
  • Pressure reducing support surfaces including:
    • Air fluidized bed
      E0194
    • Non powered advanced pressure reducing mattress
      E0371, E0373
       
    • Powered air flotation bed (low air loss therapy)
      E0193, E0372
       
    • Powered pressure reducing mattress
      E0277
       
  • Push rim activated power assist devices
    E0986

  • Repair or replacement of all DME items, as well as orthoses and prosthetics that require precertification
    E2368, E2369, E2370, E2374, E2375, E2376
  • Speech generating devices
    E2500, E2502, E2504, E2506, E2508, E2510, E2511, E2599, V5336

Medical foods

B4149, B4150, B4152, B4153, B4154, B4155, B4157, B4158, B4159, B4160, B4161, B4162, S9433, S9434, S9435

Hyperbaric oxygen therapy

0413, G0277

Proton beam therapy

Precertification review is provided by CareCore National, LLC d/b/a eviCore healthcare (eviCore), an independent company. To access the eviCore website, click here.

Sleep studies (facility based)

Precertification is performed by AIM Specialty Health®, an independent company. To access the complete list of AIM Specialty Health Sleep Disorder Management Diagnostic & Treatment Guidelines, click here.

All transplant procedures, with the exception of corneal transplants

0584T, 0585T, 0586T, 15775, 15776, 27415, 27416, 29866, 29867, 32851, 32852, 32853, 32854, 33935, 33945, 38205, 38206, 38207, 38208, 38209, 38210, 38211, 38212, 38213, 38214, 38215, 38230, 38232, 38240, 38241, 38242, 38243, 44133, 44135, 44136, 44137, 47135, 47140, 47141, 47142, 47399, 48160, 48554, 48556, 50320, 50340, 50360, 50365, 50370, 50380, 50547, G0341, G0342, G0343, S2053, S2054, S2060, S2061, S2065, S2103, S2140, S2142, S2150

Mental health/serious mental illness/substance abuse

Precertification review for these services is provided by Magellan Healthcare, Inc., an independent company.
  • Mental health and serious mental illness treatment (inpatient/partial hospitalization programs/intensive outpatient programs)  
  • Repetitive transcranial magnetic stimulation (RTMS)
  • Substance abuse treatment (inpatient/partial hospitalization programs/intensive outpatient programs)

Autism spectrum disorders

  • Applied behavioral analysis
    Precertification review for this service is provided by Magellan Healthcare, Inc., an independent company.​ 

Genetic and genomic tests requiring precertification

Precertification review is provided by CareCore National, LLC d/b/a eviCore healthcare (eviCore), an independent company. To access the eviCore website, click here.

The following list is a guide to the types of genetic and genomic tests that require precertification. Due to the volume of tests, it is not possible to list each test separately. To determine if a test requires precertification, please see the complete procedure code list for details. Please note: precertification of genetic and genomic tests applies to commercial members only.​

Hereditary cancer syndromes

  • BRCA gene testing (breast and ovarian cancer syndrome) 
  • Lynch syndrome gene testing 
  • Familial adenomatous polyposis gene testing 
  • PTEN gene testing (Cowden syndrome) 
  • General cancer type panels (such as colon, breast, or neuroendocrine cancers)

Hereditary heart diseases

  • Long QT syndrome gene testing 
  • Aortic dilation or aneurysm syndrome testing (includes Marfan syndrome)

Other full gene analysis testing

  • Cystic fibrosis full gene sequencing and deletion/duplication analysis 
  • PMP22 full gene sequencing and deletion/duplication analysis (Charcot-Marie-Tooth, hereditary neuropathy) 

Tests for many genetic disorders simultaneously

  • Expanded carrier screening panels (such as Carrier Status DNA Insight®, Counsyl Family Prep Screen, Pan-Ethnic Carrier Screening)
  • Hearing loss panels 
  • Intellectual disability panels 
  • Noonan spectrum disorders panels

Specialty oncology tests

  • Cancer gene expression or protein signature tests (such as OncotypeDX®, MammaPrint®, Afirma®, Prosigna®, HeproDX™) 
  • Tumor molecular profiling (such as FoundationOne®, neoTYPE™, OncoPlexDx®, and many others) 
  • Tissue of origin testing (for cancer of unknown primary) 
  • PCA3 testing for prostate cancer

Pharmacogenomic tests 

  • Cytochrome P450 metabolism gene testing (CYP2D6, CYP2C9, CYP2C19)
  • Specialized drug response gene panels (such as Assurex GeneSight®, GeneTrait, Genecept®, Millennium PGTSM) 
  • Warfarin response testing 
  • MGMT methylation analysis for glioblastoma

Other specialty tests

  • Coronary artery disease risk testing (such as CorusCAD®, CardioIQ®, APOE, ACE, KIF6) 
  • Heart disease risk testing (such as CorusCAD®, CardioIQ®, APOE, ACE, KIF6, MTHFR)

Genome-wide tests

  • Microarray studies 
  • Whole exome testing 
  • Whole genome testing 
  • Mitochondrial genome or nuclear testing

ANY genetic test for more than one gene or condition (often includes words like “panel" or “comprehensive" in the name)

ANY genetic test that will be billed with a non-specific procedure code

  • Billed with CPT® codes 81400-81408 
  • Billed with an unlisted code: 81479, 81599, 84999

Specialty drugs requiring precertification


All listed brands and their generic equivalents or biosimilars require precertification. This list is subject to change.

Antineoplastic agents

  • Abraxane® - J9264
  • Adcetris® - J9042
  • Alimta® - J9305
  • Avastin® - C9257 and J9035 (Note: Opthalmologic use of Avastin does not require precertification. Precertification requirements apply to all FDA-approved biosimilars to this originator product.)
  • Azedra - A9590
  • Azedra Dosimetric - A9590
  • Blenrep - J3590 and C9069
  • Blincyto™ - J9039
  • Cyramza® - J9308
  • Darzalex™ - J9145
  • Darzalex Faspro – J9144
  • Elzonris™ - J9269
  • Enhertu® - J9358
  • Erbitux® - J9055
  • Erwinaze® - J9019
  • Herceptin® - J9355 (Precertification requirements apply to all FDA-approved biosimilars to this originator product.)
  • Herceptin® Hylecta - J9356
  • Herzuma - Q5113
  • Instiladrin (pending FDA approval) - J3490 and C9399
  • Kadcyla® - J9354
  • Kanjinti™ - Q5117
  • Kyprolis® - J9047
  • Lumoxiti™ - J9313
  • Margenza™ - J3490, J3590, and C9399
  • Mvasi™ - Q5107 (Note: Opthalmologic use of Mvasi does not require precertification.)
  • Ogivri - Q5114
  • Ontruzant - Q5112
  • Padcev- J9177
  • Pemfexy - J9304
  • Perjeta® - J9306
  • Phesgo – J9316
  • Polivy - J9309
  • Poteligeo® - J9204
  • Provenge® - Q2043
  • Riabni™ - J3490, J3590, and C9399
  • Rituxan® - J9312 (Precertification requirements apply to all FDA-approved biosimilars to this originator product.)
  • Rituxan Hycela™ - J9311
  • Ruxience™ - Q5119
  • Sarclisa® - J9227
  • Taclantis™ (pending FDA approval) - J3490 and C9399
  • Tecartus™ (pending FDA approval) – J3590 and C9073
  • Trazimera™ - Q5116
  • Trodelvy™ - J9317
  • Truxima™ - Q5115
  • Xofigo®* - A9606
  • Yervoy™ - J9228
  • Zepzelca – J9223
  • Zevalin®* - A9543
  • Zirabev™ - Q5118
  • Chimeric antigen receptor t-cell (car-t) therapy; car-t cell administration, autologous – 0540T
* Precertification review is provided by CareCore National, LLC d/b/a eviCore healthcare (eviCore), an independent company. To access the eviCore website, click here.

Anti PD-1/PD-L1 human monoclonal antibodies

All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.
  • Bavencio® - J9023
  • Dostarlimab (pending FDA approval) – J3490, J3590, and C9399
  • Imfinzi™ - J9173
  • Keytruda™ - J9271
  • Libtayo® - J9119
  • Opdivo® - J9299
  • Tecentriq™ - J9022

Bone-modifying agents

  • Evenity™ - J3111
  • Prolia® - J0897
  • Xgeva® - J0897


Botulinum toxin agents

  • Botox® - J0585

Chemotherapy-induced nausea and vomiting (CINV) agents

  • Sustol® - J1627

Chimeric antigen receptor (CAR-T) therapies

All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.
  • Ciltacabtagene Autoleucel (pending FDA approval) – J3490, J3590, and C9399
  • Idecabtagene Vicleucel (pending FDA approval) – J3490, J3590, and C9399
  • Kymriah™ - Q2042
  • Lisocabtagene maraleucel (pending FDA approval) - J3490, J3590, and C9399
  • Yescarta™ - Q2041         

Colony stimulating factors

  • Fulphila™ - Q5108
  • Lapelga (pending FDA approval) - J3490, J3590, and C9399
  • Neulasta® - J2505 (Precertification requirements apply to all FDA-approved biosimilars to this originator product.)
  • Neulasta Onpro™ - J2505
  • Neupogen® - J1442
  • Nivestym™ - Q5110
  • Nyvepria™ – Q5122
  • Rolontis® (pending FDA approval) - J3490 and C9399
  • Udenyca™ - Q5111
  • Ziextenzo® - Q5120

Duchenne muscular dystrophy agents


All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.
  • Casemirsen (pending FDA approval) - J3490, J3590, and C9399
  • Viltolarsen (pending FDA approval) - J3490, J3590, and C9399

Endocrine/metabolic agents

  • Cosyntropin depot (pending FDA approval) - J3490, J3590, and C9399
  • H.P. Acthar® - J0800
  • Lutathera®* - A9513 and A9699
  • Makena® - J1726 and J1729
  • Sandostatin® LAR - J2353
  • Somatuline® depot - J1930
* Precertification review is provided by CareCore National, LLC d/b/a eviCore healthcare (eviCore), an independent company. To access the eviCore website, click here.

Enzyme replacement agents


All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.
  • Aldurazyme® - J1931
  • Brineura™ - J0567
  • Cerezyme® - J1786
  • Elaprase® - J1743
  • Elelyso® - J3060
  • Fabrazyme® - J0180
  • Kanuma® - J2840
  • Lumizyme® - J0221
  • Mepsevii™ - J3397
  • Naglazyme® - J1458
  • Pegunigalsidase Alfa (pending FDA approval) – J3490, J3590, and C9399
  • Replagal® (pending FDA approval) - J3490
  • Revcovi™ - J3590 and C9399
  • Vimizim™ - J1322
  • VPRIV® - J3385

Gene therapy

All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.
  • Luxturna™ - J3398
  • Valrox (pending FDA approval) - J3490 and C9399
  • Zolgensma® - J3399
  • Zynteglo (pending FDA approval) - J3490, J3590, and C9399

Hemophilia/Coagulation factors

All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.
  • Advate - J7192
  • Adynovate - J7207
  • Afstyla - J7210
  • Alphanate - J7186
  • Alphanine SD - J7193
  • Alprolix - J7201
  • Autoplex T - J7198
  • Bebulin VH - J7194
  • Bebulin - J7194
  • Benefix - J7195
  • Bioclate - J7192
  • Coagadex - J7175
  • Corifact - J7180
  • Eloctate - J7205
  • Esperoct- J7204
  • Feiba NF - J7198
  • Feiba VH - J7198
  • Fibryga - J7177
  • Fibryna - J7178
  • Helixate FS - J7192
  • Hemlibra - J7170
  • Hemofil-M - J7190
  • Humate-P - J7187
  • Hyate-C - J7191
  • Idelvion - J7202
  • Ixinity - J7199
  • Jivi® - J7199 and J7208
  • Koate-DV I- J7190
  • Kogenate FS - J7192
  • Kovaltry - J7207 and J7211
  • Monarc - J7190
  • Monoclate-P - J7190
  • Mononine - J7193
  • Novoeight - J7182
  • Novoseven RT - J7189
  • Novoseven - J7189
  • Nuwiq - J7209
  • Obizur - J7188
  • Profilnine SD - J7194
  • Proplex T - J7194
  • Rebinyn - J7203
  • Recombinate - J7192
  • Refacto - J7192
  • RiaSTAP - J7178
  • Rixubis - J7195 and J7200
  • Sevenfact - J7212
  • Tretten - J7181
  • Vonvendi - J7179 and J7199
  • Wilate - J7183
  • Xyntha - J7185

Hyaluronate acid products

  • Cingal (pending FDA approval) - J3490
  • Durolane® - J7318
  • Euflexxa™ - J7323
  • Gel-One® - J7326
  • Gelsyn-3™ - J7328
  • GenVisc 850® - J7320
  • Hyalgan® - J7321
  • Hymovis® - J7322
  • Supartz® - J7321
  • Synojoynt - J7331
  • Triluron - J7332
  • TriVisc™ - J7329
  • VISCO-3® - J7333

Immunological agents

  • Actemra® - J3262
  • Avsola™ - Q5121
  • Benlysta® - J0490
  • Entyvio™ - J3380
  • Ilumya™ - J3245
  • Inflectra™ - Q5103
  • Ixifi™ - Q5109
  • Orencia® - J0129
  • Remicade® - J1745 (Precertification requirements apply to all FDA-approved biosimilars to this originator product.)
  • Renflexis™ - Q5104
  • Simponi® Aria - J1602
  • Stelara® - J3357 and J335

Intravenous Immune Globulin/Subcutaneous Immune Globulin (IVIG/SCIG)

All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.
  • Intravenous Immune Globulin (IVIG)
    • Asceniv - J1599 and C9072
    • Bivigam - J1556
    • Carimune - J1566
    • Flebogamma - J1572
    • Flebogamma-Dif - J1572
    • Gammagard - J1569
    • Gammagard Liquid - J1569
    • Gammagard S/D - J1566
    • Gammaked - J1561
    • Gammaplex - J1557
    • Gamunex-C - J1561
    • Octagam - J1568
    • Panzyga - J1599
    • Privigen - J1459 
  • Subcutaneous Immune Globulin (SCIG)
    • Cutaquig - J7799
    • Cuvitru - J1555
    • Hizentra - J1559
    • Hyqvia - J1575
    • Xembify - J1558

Multiple sclerosis agents

All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.
  • Lemtrada® - J0202
  • Ocrevus™ - J2350
  • Tysabri® - J2323

Ophthalmic agents

  • Abicipar (pending FDA approval) - J3490, J3590, and C9399
  • Beovu® - J0179
  • Eylea® - J0178
  • Lucentis® - J2778
  • Macugen® - J2503
  • Ranibizumab Biosimilar (pending FDA approval) – J3490, J3590, and C9399
  • Tepezza® - J3241

Pulmonary arterial hypertension

All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.
  • Flolan® - J1325
  • Remodulin® - J3285
  • Revatio® - J3490 and C9399
  • Trevyent (pending FDA approval) - J3490 and C9399
  • Tyvaso® - J7686
  • Veletri® - J1325
  • Ventavis® - Q4074

Respiratory agents

  • Cinqair® - J2786
  • Fasenra™ - J0517
  • Nucala® - J2182
  • Synagis® - 90378
  • Xolair® - J2357

Respiratory enzymes (Alpha-1 antitrypsin)

All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.
  • Aralast - J0256
  • Glassia™ - J0257
  • Prolastin® - J0256
  • Zemaira® - J0256

Miscellaneous therapeutic agents

  • Adakveo® - J0791
  • Ampligen® (pending FDA approval) - J3490
  • Crysvita - J0584
  • Evianacumab (pending FDA approval) – J3490, J3590, and C9399
  • Exenatide sustained-release ITCA 650 (pending FDA approval) - J3490
  • Gamifant® - J9210
  • Givlaari - J0223
  • Ilaris - J0638
  • Inclisiran (pending FDA approval) – J3490, J3590, and C9399
  • Inebilizumab (pending FDA approval) - J3490 and C9399
  • Krystexxa - J2507
  • Onpattro® - J0222
  • Oxlumo™ – J3490, J3590, and C9399
  • Radicava - J1301
  • Reblozyl® - J0896
  • Remune (pending FDA approval) - J3490
  • Rethymic™ (RVT-802) (pending FDA approval) - J3490, J3590, and C9399
  • Soliris® - J1300 (Precertification requirements apply to all FDA-approved biosimilars to this originator product.)
  • Spinraza - J2326
  • Trogarzo - J1746
  • Ultomiris™ - J1303
  • Uplizna – J1823
  • Vyepti™ - J3032​
  • Xiaflex® – J0775

Revisions

​​

​January 1, 2021 ​

The following revisions were incorporated into the January 1, 2021 update.

Additions, services 

The entire section entitled Genetic and genomic tests requiring precertification has been added. 

Additions, drugs added 

Antineoplastic agents

  • Margenza™ - J3490, J3590, and C9399
  • Riabni™ - J3490, J3590, and C9399
  • Tecartus™ (pending FDA approval) – J3590 and C9073
  • ​Chimeric antigen receptor t-cell (car-t) therapy; car-t cell administration, autologous – 0540T​​​

Anti PD-1/PD-L1 human monoclon​​al antibodies

  • ​Dostarlimab (pending FDA approval) – J3490, J3590, and C9399 

Chimeric antigen receptor (CAR-T) t​​herapies

  • Ciltacabtagene Autoleucel (pending FDA approval) – J3490, J3590, and C9399
  • Idecabtagene Vicleucel (pending FDA approval) – J3490, J3590, and C9399 

Colony stimulat​​​ing factors

  • Neupogen® - J1442
  • ​Nyvepria™ – Q5122 

Enzyme replacement a​​gents

  • ​Pegunigalsidase Alfa (pending FDA app​roval) – J3490, J3590, and C9399 

Ophthalmic age​​​​nts

  • ​Ranibizumab Biosimilar (pending FDA approval) – J3490, J3590, and C9399 

Miscellaneous therap​​​eutic agents

  • Evianacumab (pending FDA approval) – J3490, J3590, and C9399
  • Inclisiran (pending FDA approval) – J3490, J3590, and C9399
  • Oxlumo™ – J3490, J3590, and C9399
  • ​Xiaflex® – J0775 

Additions, codes ad​ded
 

Antineoplastic agen​​​ts

  • Blenrep – C9069
  • Darzalex Faspro – J9144
  • Phesgo – J3590 and C9399
  • Trodelvy™ - J9317
  • ​Zepzelca™ - J9223 

Hemophilia/Coagulation f​​​actors

  • ​Sevenfact – J7212 

Intravenous Immu​​​ne Globulin/Subcutaneous Immune Globulin (IVIG/SCIG)

  • ​Asceniv – C9072 

Miscellaneous therapeu​​tic agents

  • ​Uplizna – J1823 

Additions, language added
 

Antineoplastic ag​​​ents

  • Instiladrin – (pending FDA approval)
  • Taclantis™ – (pending FDA approval) 

Colony stimulating​​ factors

  • ​Rolontis® – (pending FDA approval) 

Duchenne muscular dyst​​roph​​y agents


All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year. 

Gene ​​​therapy

  • ​Valrox – (pending FDA approval) 

Pulmonary arterial hyperte​​nsion


All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year. 
  • ​Trevye​nt – (pending FDA approval)

Miscellaneous therapeutic agen​​​ts

  • ​Inebilizumab – (pending FDA approval)

__________​​_______________________________________________________________


Deletions, drugs removed 

Antineoplastic agent​​s

  • Halaven® – J9719
  • Jevtana® – J9043
  • ​Margetuximab (pending FDA approval) - J3490, J3590, and C9399 

Duchenne muscular dystrop​hy agents

  • Exondys-51™ – J1428
  • ​Vyo​ndys 53 – J1429 

Miscellaneous therapeutic ag​​​en​​ts

  • Ravulizumab – J3490
  • ​Syl​vant™ – J2860 

Deletions, code​s removed 

Reconstructive procedures and poten​​​tially cosmetic procedures

  • Breast Reconstruction – 19366
  • ​Breast Augmentation/Mammoplasty – 19324 

Antineoplastic agents​​​

  • Blenrep – C9399
  • Darzalex Faspro – C9062
  • Phesgo – J9316 and C9399
  • Trodelvy™ – J3590 and C9066
  • ​Zepzelca™ – J3490 and C9399 

Hemophilia/Coagulation factors​​​

  • ​Sevenfact – J7189

Miscellaneo​​​​​us therapeutic agents

  • ​Uplizna – J3490 and C9399 

Deletions, language removed 

Ophthalmic ag​​ents


All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.​


 

This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.